Gallstone Disease and Cholecystectomy

Executive Summary

Gallstone disease is one of the most common and most costly digestive disorders in the world; yet the real clinical burden arises not from the presence of stones but from the complications that develop in a minority of patients. That single sentence is the core of the entire management logic.

Twenty-first-century data place the pooled global prevalence of gallstones at roughly 6 percent, with a marked geographic, sex and metabolic gradient. Historically, higher figures of 10–20 percent have been reported in Western populations — a difference that reflects definitions, populations and screening methods rather than a genuine biological gulf. In most patients stones stay silent for life; only about 1–4 percent of people with silent stones develop biliary pain each year. It is precisely this benign natural history that underpins the recommendation against prophylactic surgery for silent stones.

Stone formation is the product not of a single defect but of several interwoven mechanisms. Cholesterol stones — the dominant group in the West — arise where cholesterol supersaturation of bile, a sluggish gallbladder (hypomotility), crystal nucleation and a permissive contribution from the gut and biliary microbiota intersect, on a strong genetic background (particularly the ABCG5/ABCG8 transporter). Pigment stones instead carry the imprint of bilirubin metabolism, haemolysis and bacterial or parasitic biliary infection.

Diagnosis rests on transabdominal ultrasonography for gallbladder stones and on a stepwise pathway for common bile duct stones (biochemistry → MRCP/EUS → ERCP). In treatment, laparoscopic cholecystectomy is the definitive solution and the global gold standard. In acute calculous cholecystitis, early laparoscopic cholecystectomy is recommended for operable patients, preferably within about seven days of symptom onset and during the same admission. Robotic cholecystectomy is safe and feasible; however, it has not demonstrated a clinically meaningful advantage over laparoscopy, has cost more, and has produced a higher bile duct injury signal in early experience and registry data. Oral bile acid dissolution with ursodeoxycholic acid is today a slow-acting, high-recurrence niche therapy confined to small, non-calcified cholesterol stones in selected patients unfit for surgery.

Four principles at a glance

• Silent stones are observed; symptomatic stones are operated on. Prophylactic cholecystectomy is unnecessary in most asymptomatic patients; once symptoms begin, elective surgery is indicated because recurrence and complications accumulate.
• Early surgery wins in acute cholecystitis. Early laparoscopic cholecystectomy during the same admission is superior to a delayed strategy and, in high-risk patients, to percutaneous drainage (CHOCOLATE).
• The anchor of safe cholecystectomy is the Critical View of Safety. If the anatomy is unclear, subtotal cholecystectomy, a fundus-first approach or conversion to open surgery is not a failure but a mark of sound judgement.
• Robotic surgery is an alternative, not a proven advantage. In standard cases the decision is shaped by cost, expertise and a safety signal, not by outcome superiority.

The frontier of the field is shifting from the question of how to remove the gallbladder more elegantly to the question of how to build a surgery in which injuring the bile duct is impossible and, ultimately, a prevention strategy in which the stone never forms. Near-infrared fluorescence cholangiography and artificial-intelligence-assisted anatomy recognition aim to drive injury to zero; genetic, bile acid and microbiome-based strategies aim to prevent stone formation in the first place. Delivering on that promise depends on adequately powered studies with hard clinical endpoints that can close the stubborn gap between mechanistic plausibility and demonstrated patient benefit.

A Short History of Gallbladder Surgery

The modern history of this field can be summarised in two great transitions. The first is the replacement of open cholecystectomy by the laparoscopic approach from 1987 onwards; that transition reshaped surgery as a whole by markedly reducing pain, hospital stay and mortality. The second is the reconstruction of the diagnostic and clearance logic for common bile duct stones as endoscopic (ERCP) and cross-sectional (MRCP, EUS) techniques matured.

The result is a highly mature treatment paradigm today: ultrasound first, then a stepwise approach to bile duct stones; laparoscopic cholecystectomy as definitive treatment; early surgery in acute cholecystitis; and a safety culture dedicated to preventing bile duct injury. Robotic and single-incision approaches have widened this toolbox, but they have not dethroned laparoscopy on the grounds of outcome superiority.

Epidemiology and Disease Burden

Gallstone disease is one of the highest-volume causes of elective and emergency abdominal surgery worldwide. In the United States alone it accounts for more than a million hospital encounters a year and is among the principal drivers of the cost of digestive disease.

Recent meta-analyses put numbers on this. A 2024 systematic review covering 115 studies and more than 32.6 million participants estimated a pooled global prevalence of 6.1 percent (95 percent CI 5.6–6.5), higher in women than in men (7.6 versus 5.4 percent), highest in South America and lowest in Asia (11.2 versus 5.1 percent). A second meta-analysis of 139 studies reported a similar global figure (5.86 percent) and confirmed female sex, age over 50, high body mass index and family history — but not smoking, alcohol or a vegetarian diet — as significantly associated factors. Ethnic extremes are well documented: Native American populations such as the Chilean Mapuche and the Pima in the United States have the highest rates in the world, attributable to the ABCG8 D19H variant.

Grasping the scale frames every remaining decision: prevalence is so high that even small proportional improvements in treatment and prevention strategies translate into enormous absolute population benefit. A knowledge gap must also be noted, however — reliable incidence data from low- and middle-income countries are sparse.

Normal Hepatobiliary Anatomy

Competent gallbladder surgery is, in essence, applied anatomy; every safe manoeuvre depends on reading this map correctly.

The gallbladder

The gallbladder is a pear-shaped reservoir lodged in the fossa on the visceral surface of the liver at the junction of segments IVb and V (typically 7–10 cm long, with a functional capacity of 30–50 mL). It is divided into fundus, body, infundibulum and neck; the neck narrows into the cystic duct. Hartmann's pouch, a common outpouching of the infundibulum, is the site where stones most often impact. The wall comprises columnar epithelium (with absorptive folds and crypt-like Rokitansky–Aschoff sinuses), lamina propria, a muscularis (it contains no true muscularis mucosae or submucosa — an anatomical detail that affects cancer staging), perimuscular connective tissue and serosa.

The biliary tree

The right and left hepatic ducts unite to form the common hepatic duct. Where the cystic duct joins the common hepatic duct, the common bile duct is formed; its diameter normally does not exceed 6–7 mm and increases slightly with age and after cholecystectomy. The common bile duct descends behind the first part of the duodenum, passes through the head of the pancreas and terminates with the main pancreatic duct at the ampulla of Vater, which is encircled by the sphincter of Oddi that regulates biliary and pancreatic flow. The cystic duct is lined by the spiral valves of Heister.

Calot's triangle and the Critical View of Safety

Bounded by the cystic duct, the common hepatic duct and the inferior edge of the liver, this triangle contains the cystic artery (usually a branch of the right hepatic artery), Lund's lymph node and connective tissue. Clearing this triangle of fat and fibrous tissue to achieve the Critical View of Safety — opening the hepatocystic triangle, exposing the lower gallbladder bed and confirming that only two structures enter the gallbladder, namely the cystic duct and the cystic artery — is the single most important technical safeguard against bile duct injury.

Anatomical variation is the rule rather than the exception and underlies most iatrogenic injuries: an aberrant or replaced right hepatic artery, a short or long cystic duct, accessory bile ducts draining directly into the gallbladder bed (ducts of Luschka) and variant right posterior sectoral ducts. Recognising these variants — increasingly with the help of intraoperative imaging — is a precondition of safe surgery.

Physiology and Bile Formation

Between meals the gallbladder stores hepatic bile and concentrates it 5- to 10-fold through active epithelial absorption of sodium, chloride and water. With a meal — particularly in response to duodenal fat and protein — enteroendocrine I-cells release cholecystokinin, which contracts the gallbladder smooth muscle, relaxes the sphincter of Oddi and empties concentrated bile into the duodenum. Vagal tone, motilin and FGF19 also tune motility and bile acid synthesis. Poor gallbladder emptying (stasis) is a key permissive factor in stone formation.

The principal solutes of bile are bile acids (about 67 percent of solids), phospholipids (chiefly lecithin, ~22 percent), cholesterol (~4 percent), bilirubin, proteins and electrolytes; about 95 percent of the mass of bile is water. Water-insoluble cholesterol is held in solution by incorporation into mixed micelles and vesicles together with bile salts and phospholipids. The physicochemical balance among these three lipids — classically depicted in the Admirand–Small triangular phase diagram — determines whether cholesterol stays dissolved.

Bile acid synthesis and the enterohepatic circulation

The primary bile acids — cholic acid and chenodeoxycholic acid — are synthesised from cholesterol in hepatocytes. The classic (neutral) pathway, whose rate-limiting step is cholesterol 7α-hydroxylase (CYP7A1), carries out most of the synthesis. Bile acids are conjugated with glycine or taurine, secreted into bile and reabsorbed in the terminal ileum by the ASBT transporter, returning to the liver through the portal vein — the enterohepatic circulation, which cycles 6–10 times a day and preserves about 95 percent of the pool. Gut bacteria convert primary bile acids into secondary bile acids (deoxycholic and lithocholic acid). The nuclear receptor FXR and intestinal FGF19 signalling suppress CYP7A1 by feedback, thereby linking bile acid homeostasis, cholesterol homeostasis and — as newer data show — the microbiome.

Canalicular ABC transporters govern the lithogenic potential of bile: ABCG5/ABCG8 pumps cholesterol into bile; ABCB4 (MDR3) secretes phosphatidylcholine; ABCB11 (BSEP) secretes bile salts. The cholesterol-to-solubiliser ratio these pumps establish is decisive: excessive ABCG5/8 activity or insufficient ABCB4 activity supersaturates bile with cholesterol.

Classification of Gallstones

Stones are grouped by their dominant composition, and the epidemiological and mechanistic differences between these groups matter.

Cholesterol stones (~75–90 percent in the West). More than half — often more than 90 percent — is cholesterol monohydrate, overlaid by a glycoprotein matrix and variable calcium salts. They are usually single or few in number, larger, yellow-green and radiolucent (only about 15–20 percent contain enough calcium to be visible on plain film). In principle this is the only stone type amenable to oral dissolution.

Black pigment stones (~10–20 percent). Formed in sterile bile from calcium bilirubinate polymer with calcium phosphate and carbonate. They are associated with chronic haemolysis (sickle cell disease, hereditary spherocytosis, thalassaemia), cirrhosis, ileal disease or resection (Crohn's) and advanced age. They are small, hard and often radiopaque, and they form in the gallbladder.

Brown pigment stones (~5 percent). Formed from calcium bilirubinate, fatty acid calcium soaps and cholesterol against a background of biliary stasis with bacterial or parasitic infection. Bacterial β-glucuronidase and phospholipase deconjugate bilirubin and break down phospholipids, precipitating calcium bilirubinate. These are the characteristic stones of the bile ducts (primary common bile duct stones) and of recurrent pyogenic cholangitis; they are more frequent in East and Southeast Asia.

Pathophysiology of Stone Formation

Contemporary models describe cholesterol stone formation as the convergence of four defects; this is why the disease is at once metabolic, mechanical and microbial.

1. Cholesterol supersaturation of bile. Excess secretion of cholesterol relative to bile salts and phospholipids (through increased ABCG5/8 activity, obesity and insulin resistance, a high-calorie, high-fat diet, oestrogens and rapid weight loss) drives the cholesterol saturation index above 1.
2. Accelerated nucleation. Pronucleating factors (mucin glycoproteins, immunoglobulins, aminopeptidase-N) shift the balance towards crystals, while antinucleators are relatively deficient. Cholesterol monohydrate crystals precipitate from unstable vesicles.
3. Gallbladder hypomotility and stasis. Impaired emptying (cholesterol loading of the muscular wall, pregnancy, prolonged fasting or total parenteral nutrition, somatostatin analogues, spinal cord injury, diabetic autonomic neuropathy) prolongs the residence time of supersaturated bile and allows crystals to aggregate.
4. The gut and biliary microbiome and intestinal factors. An altered microbiota changes the bile acid pool and cholesterol absorption; slowed transit raises deoxycholate and thereby saturation. Mucin secretion acts as a scaffold.

Crystals aggregate within a mucin gel to form macroscopic stones. In pigment stones the mechanism differs: black stones arise when bilirubin load or solubility changes (chronic haemolysis, cirrhosis, ileal disease), whereas brown stones arise when bacteria and parasites in stagnant bile enzymatically generate insoluble calcium bilirubinate — that is, fundamentally through an infection and stasis mechanism.

Risk Factors

The classic six-F mnemonic — Female, Fat, Forty, Fertile, Fair, Family — captures much of the risk; the evidence-based picture, however, is broader. Indeed, in the largest current pooled analysis several classic risk factors (smoking, alcohol, serum lipid levels) were not significant — a good example of how old single-study associations can be revised by pooled analysis.

Genetics

Gallstone disease is moderately heritable; twin studies suggest that roughly 25–30 percent of susceptibility is genetic. The dominant locus reproducible across ancestries is ABCG5/ABCG8, which encodes the canalicular cholesterol half-transporter. The gain-of-function ABCG8 p.D19H (rs11887534) variant, which increases biliary cholesterol secretion, is the strongest common risk allele and is particularly prominent in high-prevalence Latin American populations.

Large genome-wide association studies have widened the map: Joshi et al. (2016) added SULT2A1, TM4SF4, GCKR and CYP7A1; Ferkingstad et al. (2018) identified about 20 loci in 27,174 cases and 736,838 controls; integrated UK Biobank and FinnGen meta-analyses (71,384 cases) have proposed new loci of therapeutic interest.

Clinically important monogenic contributions also exist: ABCB4 (MDR3) deficiency causes low-phospholipid-associated cholelithiasis — early-onset, recurrent, intrahepatic cholesterol stones — and predisposes to intrahepatic cholestasis of pregnancy; UGT1A1 variants (Gilbert's syndrome) raise unconjugated bilirubin and thereby the risk of pigment stones. In general, bilirubin (pigment) stones are more genetically determined than cholesterol stones. Polygenic risk scores are an active line of research for identifying individuals who might benefit from preventive strategies.

Clinical Presentation

Asymptomatic (silent) stones. These are the majority. Classic natural history cohorts show that only about 1–4 percent of people with silent stones develop biliary pain each year, and that serious complications without antecedent pain are rare. Cumulatively, roughly 20 percent become symptomatic over 15–20 years. This benign course is the basis of the recommendation against prophylactic cholecystectomy for silent stones in most patients.

Biliary colic (symptomatic cholelithiasis). The name is misleading — the pain is typically constant rather than colicky. It is a steady pain in the right upper quadrant or epigastrium, often radiating to the right scapula and back, triggered by a fatty meal, lasting from 30 minutes to a few hours and then resolving; nausea frequently accompanies it. It reflects transient obstruction of the cystic duct without sustained inflammation. Recurrence is the rule, and that is what justifies elective cholecystectomy.

Acute (calculous) cholecystitis. Persistent obstruction of the cystic duct leads to gallbladder distension, wall inflammation and oedema, and possible secondary infection. Findings include right upper quadrant pain lasting more than four to six hours, fever, leukocytosis and a positive Murphy's sign (inspiratory arrest on palpation of the right upper quadrant). Untreated, it may progress to empyema, gangrene or perforation.

Chronic cholecystitis. Recurrent inflammation leads to a fibrotic, thick-walled, poorly functioning gallbladder; when the wall is calcified we speak of a porcelain gallbladder. It presents with recurrent biliary pain and dyspepsia.

Choledocholithiasis (common bile duct stones). This may be asymptomatic or may cause obstructive jaundice, dark urine, pale stools, pruritus and right upper quadrant pain; it carries the risk of ascending cholangitis (Charcot's triad: fever, jaundice, right upper quadrant pain; Reynolds' pentad adds hypotension and confusion) and of gallstone pancreatitis.

Rare syndromes. Mirizzi syndrome (an infundibular or cystic duct stone compressing the common hepatic duct), gallstone ileus (a large stone passing through a cholecystoenteric fistula and classically obstructing the bowel at the ileocaecal valve; Rigler's triad on imaging), Bouveret syndrome (the gastric outlet obstruction variant) and gallbladder cancer.

Diagnostic Assessment and Imaging

First line: transabdominal ultrasonography

Ultrasound is the imaging modality of first choice when gallbladder stones are suspected — it is non-invasive, inexpensive, radiation-free and widely available. Sensitivity and specificity for gallbladder stones exceed 95 percent. Findings include mobile echogenic foci casting an acoustic shadow; in acute cholecystitis, wall thickening (over 3 mm), pericholecystic fluid, gallbladder distension and a sonographic Murphy's sign. Ultrasound is less sensitive for visualising common bile duct stones directly but does detect duct dilatation. WSES 2020 likewise confirms ultrasound as the preferred first modality in acute calculous cholecystitis.

Other modalities

HIDA scintigraphy has the highest sensitivity and specificity for acute cholecystitis (non-visualisation of the gallbladder means cystic duct obstruction); it is useful when ultrasound is equivocal and in functional gallbladder disorders (a cholecystokinin-stimulated ejection fraction below 35–38 percent supports biliary dyskinesia) — but it is slow and not widely available. Computed tomography is limited for radiolucent stones themselves but is valuable for complications (perforation, emphysematous or gangrenous cholecystitis, gallstone ileus), staging and differential diagnosis. Magnetic resonance cholangiopancreatography (MRCP) is the best non-invasive test for common bile duct stones (sensitivity and specificity ~90–95 percent); it provides a contrast-free, radiation-free ductal map and is preferred in intermediate-risk stratification. Endoscopic ultrasound is equivalent or superior to MRCP for small distal duct stones and sludge; it is invasive but can be combined with ERCP in the same session. ERCP is now essentially therapeutic; because of a 5–10 percent adverse event rate it is reserved for high-probability or confirmed duct stones.

Laboratory tests

In biliary colic and uncomplicated stones, laboratory tests are typically normal. Acute cholecystitis shows leukocytosis with a left shift and raised CRP; mild transaminase or ALP elevation may occur — marked hyperbilirubinaemia, however, suggests an accompanying duct stone or Mirizzi syndrome. Choledocholithiasis and cholangitis show a cholestatic pattern of elevation (ALP, GGT, conjugated bilirubin); cholangitis adds leukocytosis and positive blood cultures. In gallstone pancreatitis, lipase and amylase exceed three times the upper limit of normal; in acute pancreatitis, an ALT above three times the upper limit strongly indicates a biliary cause. No single laboratory value confirms or excludes the disease on its own.

Differential diagnosis

Peptic ulcer, reflux, functional dyspepsia, acute pancreatitis, hepatitis or liver abscess, right pyelonephritis or renal colic, right lower lobe pneumonia, appendicitis, inferior myocardial ischaemia, Fitz-Hugh–Curtis syndrome and acalculous functional gallbladder disorder should be considered. Sphincter of Oddi dysfunction enters the differential diagnosis of post-cholecystectomy pain.

Overview of Treatment and Follow-up of Asymptomatic Stones

Management is determined by whether the stones are symptomatic and by the presence of complications.

For asymptomatic gallbladder stones, observation — a watch-and-wait stance — applies in the great majority. Prophylactic cholecystectomy is not routinely recommended, because the annual risk of symptoms and complications is low and surgery itself is not without cost (moderate-certainty evidence; consistent with guidelines including EASL 2016). Nevertheless, selective prophylactic surgery is considered in selected high-risk situations: porcelain gallbladder (particularly stippled or incomplete calcification), large stones (a 3 cm threshold is often used), gallbladder polyps meeting size and risk thresholds, an abnormal pancreaticobiliary junction or choledochal cyst, certain haemolytic anaemias (often at the time of splenectomy) and populations at very high risk of gallbladder cancer. Incidental (concomitant) cholecystectomy during another abdominal operation is individualised.

In symptomatic cholelithiasis (biliary colic), elective laparoscopic cholecystectomy is indicated — because symptoms recur and the risk of complications rises after the first biliary event. Complicated disease (acute cholecystitis, choledocholithiasis, cholangitis, gallstone pancreatitis) is managed along the pathways set out in the relevant sections.

Acute Cholecystitis: Severity and Timing

The Tokyo Guidelines 2018 preserved the 2013 diagnostic criteria and severity grading unchanged after validation. Diagnosis requires local inflammation (Murphy's sign; a right upper quadrant mass, pain or tenderness), systemic inflammation (fever, raised CRP and white cell count) and imaging findings; the first two groups make the diagnosis suspected, and all three make it definite.

Severity grading determines timing and setting:

• Grade I (mild): no organ dysfunction; mild gallbladder inflammation.
• Grade II (moderate): for example a white cell count above 18,000, a palpable tender right upper quadrant mass, duration beyond 72 hours, or marked local inflammation (gangrenous or emphysematous cholecystitis, pericholecystic or hepatic abscess, biliary peritonitis).
• Grade III (severe): accompanying organ dysfunction (cardiovascular, neurological, respiratory, renal, hepatic or haematological).

Treatment algorithm. In patients who can tolerate surgery (for example a Charlson comorbidity index of 5 or below and an ASA physical status of 2 or below), early laparoscopic cholecystectomy is recommended for Grades I and II. For Grade III, Tokyo 2018 moved away from blanket avoidance and permitted laparoscopy in selected patients meeting strict criteria at experienced centres; otherwise gallbladder drainage followed by interval surgery is indicated.

WSES 2020 operationalises this: early laparoscopic cholecystectomy, preferably within seven days of symptom onset and during the same admission, is first-line treatment and the gold standard; it should be deferred only in septic shock or in the presence of an absolute anaesthetic contraindication. Laparoscopy is feasible and safe even in patients over 80, in pregnancy and in Child–Pugh A/B cirrhosis. If the anatomy is unclear, subtotal cholecystectomy is preferred over hazardous dissection, and conversion to open surgery is not a failure but a mark of sound judgement. In high-risk and unfit patients, gallbladder drainage (percutaneous cholecystostomy) buys time; however, the CHOCOLATE randomised trial found early laparoscopic cholecystectomy superior to percutaneous drainage in high-risk patients able to tolerate surgery (fewer complications and reinterventions).

Antibiotic use. After early surgery for uncomplicated cholecystitis, postoperative antibiotics are generally unnecessary; complicated or high-grade disease requires targeted antimicrobial therapy in addition to source control.

Medical Treatment and Stone Dissolution

Oral bile acid dissolution. Ursodeoxycholic acid (UDCA, ursodiol), a hydrophilic bile acid, lowers biliary cholesterol saturation by reducing hepatic cholesterol secretion and enriching the bile acid pool, and slowly dissolves cholesterol crystals. The effect is real but modest and highly selective:

• The ideal candidate: a patient with small (under 5–10 mm), non-calcified (radiolucent) cholesterol stones in a functioning gallbladder with a patent cystic duct, who declines surgery or is unfit for it.
• A meta-analysis of randomised trials reported complete dissolution in about 38 percent of radiolucent stones with more than six months of UDCA at more than 7 mg/kg per day; stones under 10 mm dissolve markedly more often. Higher rates have been reported with strict selection (small, non-calcified, floating stones).
• Limitations: it is slow (6–24 months); it is ineffective for pigment, calcified or large stones and in a non-functioning gallbladder; and recurrence of 30–50 percent is seen within five years of stopping treatment, because the underlying lithogenic state persists. Set against the safety and definitiveness of laparoscopy, UDCA is a niche therapy today.

Adjunctive uses. UDCA reduces stone formation during rapid weight loss and bariatric surgery (moderate evidence). Combination with chenodeoxycholic acid or terpene preparations modestly improves dissolution and recurrence prevention in some studies; however, chenodeoxycholic acid alone causes diarrhoea and hepatotoxicity and has largely been abandoned. There is as yet no effective stone-prevention pill for the general population.

Extracorporeal shock wave lithotripsy (ESWL). Used in the 1990s for selected solitary radiolucent gallbladder stones (together with UDCA), it has largely been abandoned for gallbladder stones because of recurrence and the success of laparoscopy; it retains a role as an adjunct to ERCP for difficult bile duct stones.

Nutritional Management

Prevention and risk reduction (moderate to low certainty). The evidence supports a diet rich in fibre, unsaturated (particularly mono- and polyunsaturated) fat, fruit, vegetables, whole grains and moderate coffee, regular physical activity, and avoidance of prolonged fasting and rapid, crash weight loss; gradual and sustainable weight management lowers risk. A pattern high in refined carbohydrate and saturated fat and low in fibre raises risk. During medically supervised rapid weight loss or bariatric surgery, UDCA prophylaxis and slower weight targets reduce new stone formation.

Symptomatic (preoperative) patients. While awaiting surgery, a low-fat diet and avoidance of large fatty meals reduce cholecystokinin-mediated gallbladder contraction and therefore colic attacks — this is a symptomatic measure, not a curative one.

After cholecystectomy. Most patients return to a normal diet within weeks. Because bile now drips continuously into the duodenum rather than being stored and concentrated, a minority experience fat intolerance, bloating or bile acid (choleretic) diarrhoea; this is usually transient. Gradual reintroduction of fats, small and frequent meals at first, adequate fibre and — if bile acid diarrhoea persists — bile acid sequestrants (cholestyramine, colesevelam) are effective. There is no evidence that permanent dietary restriction is needed in most patients; individualised adjustment suffices.

ERCP and the Management of Bile Duct Stones

Risk stratification (ASGE 2019). Because ERCP carries a 5–10 percent adverse event rate (chiefly post-ERCP pancreatitis at ~5–7 percent, plus bleeding, perforation and cholangitis), the probability of a common bile duct stone is stratified before any invasive procedure in symptomatic cholelithiasis:

• High probability (proceed directly to ERCP): a duct stone on imaging; ascending cholangitis; or a total bilirubin above 4 mg/dL together with a dilated duct.
• Intermediate probability (confirmatory imaging first — MRCP, endoscopic ultrasound or intraoperative cholangiography): such as abnormal liver tests, age over 55, or a dilated duct alone.
• Low probability (cholecystectomy without additional biliary imaging): normal liver tests and no duct dilatation.

Validation studies report that the 2019 criteria are more specific but less sensitive than those of 2010; while they reduce unnecessary diagnostic ERCP, they still perform suboptimally — which is why confirmation with endoscopic ultrasound or MRCP is increasingly preferred for intermediate risk, and even for some high-risk situations other than cholangitis. The ESGE criteria are similar.

Therapeutic ERCP. Sphincterotomy with balloon or basket extraction clears most duct stones; large and difficult stones may require mechanical lithotripsy, large-balloon dilatation after sphincterotomy, or cholangioscopy-guided electrohydraulic or laser lithotripsy. Timing: in gallstone pancreatitis with accompanying cholangitis or persistent biliary obstruction, urgent ERCP (within 24–48 hours) is indicated; it is not routine in predicted mild biliary pancreatitis without obstruction. Options for duct stones are preoperative ERCP with laparoscopic cholecystectomy, single-session laparoscopic cholecystectomy with laparoscopic bile duct exploration, or intraoperative or postoperative rendezvous ERCP. After biliary pancreatitis or duct clearance, cholecystectomy during the same admission is recommended to prevent recurrence.

Percutaneous and Drainage Treatments

Percutaneous cholecystostomy is image-guided drainage of the gallbladder (usually with ultrasound or computed tomography) by a transhepatic or transperitoneal catheter. In high-risk and unfit patients with acute cholecystitis (severe comorbidity, septic shock precluding immediate surgery) it is a temporising measure; it converts a septic focus into a controlled one. Even so, the CHOCOLATE randomised trial and WSES 2020 find early laparoscopic cholecystectomy superior to percutaneous drainage in high-risk patients able to tolerate surgery, because drainage is associated with more complications, reinterventions and readmissions and does not treat the underlying stones — many patients eventually require interval cholecystectomy. Percutaneous cholecystostomy retains its value when surgery is genuinely contraindicated. Endoscopic gallbladder drainage (transpapillary or endoscopic-ultrasound-guided cholecystoduodenostomy with a lumen-apposing metal stent) is an emerging alternative at expert centres.

Laparoscopic Cholecystectomy: The Gold Standard

Since its first performance in 1987, laparoscopic cholecystectomy has become the global gold standard for symptomatic gallstone disease and acute cholecystitis, displacing open surgery in the great majority of cases. A recent meta-analysis covering 85 studies and more than 7.5 million patients confirms its superiority over open cholecystectomy strikingly: markedly lower mortality (relative risk ~0.16), fewer complications (relative risk ~0.46) and a hospital stay about four days shorter. Laparoscopic cholecystectomy today accounts for 85–95 percent of all cholecystectomies.

Technical essentials

Pneumoperitoneum; typically four ports or fewer; dissection of the hepatocystic triangle to the Critical View of Safety before the cystic duct and artery are clipped and divided; and removal of the gallbladder from the liver bed. The bail-out strategies used when the anatomy is not safe — subtotal (fenestrating or reconstituting) cholecystectomy, a fundus-first approach or conversion to open surgery — are the core of bile duct injury prevention and are endorsed as good judgement (the SAGES Safe Cholecystectomy programme).

Indications and cautions

Symptomatic cholelithiasis; acute or chronic calculous cholecystitis; biliary dyskinesia (a low HIDA ejection fraction together with typical pain); gallstone pancreatitis (after recovery, during the same admission); selected asymptomatic patients; gallbladder polyps meeting threshold criteria. Relative contraindications and cautions: uncorrectable coagulopathy, inability to tolerate pneumoperitoneum or general anaesthesia, suspected gallbladder cancer (an oncological resection rather than simple laparoscopy may be required) and end-stage cirrhosis with portal hypertension (subtotal techniques help).

Intraoperative imaging

Intraoperative cholangiography and laparoscopic ultrasound assess ductal anatomy and detect duct stones; debate continues over whether cholangiography should be routine or selective — selective use guided by risk and intraoperative findings is common, whereas it is argued that routine use reduces the severity of injury through earlier recognition. Near-infrared fluorescence cholangiography is discussed in the section on future technologies.

Robotic, Single-Incision and NOTES Approaches

Robotic cholecystectomy. Robotic platforms offer three-dimensional vision, wristed instruments and tremor filtration; adoption is rising (regionally from under 1 percent to 3–26 percent). Yet the weight of evidence shows no clinically meaningful advantage over laparoscopy in benign gallbladder disease: meta-analyses find comparable complication and mortality profiles (relative risk for mortality ~1.00) but higher cost and often longer operative and room times. More critically, a large registry analysis (Kalata et al., JAMA Surgery 2023) reported a higher rate of bile duct injury with robotic cholecystectomy than with laparoscopy, and Sheetz and Dimick (2024) described a surgeon-level learning curve effect on injury risk.

Some large series using routine indocyanine green report favourable robotic outcomes; the technology may be useful in selected difficult cases or particular settings. But current high-certainty evidence does not support replacing laparoscopy with robotics on the grounds of outcome; today the decision is shaped by local expertise, cost and training rather than by demonstrated clinical benefit (moderate certainty for equivalence, with a safety signal that warrants caution).

Single-incision laparoscopic surgery (SILS). It improves cosmesis but is associated with more incisional hernias, longer operative times and a possibly higher risk of bile duct injury; it has not become standard.

NOTES. Transvaginal or transgastric scarless cholecystectomy is largely investigational; it is limited by closure and infection concerns, the need for special equipment and the absence of outcome superiority. NOTES is better regarded as a driver of endoscopic innovation than as a mainstream treatment.

Open Cholecystectomy and Conversion

Once universal, open cholecystectomy is now reserved for situations in which laparoscopy is unsafe or unavailable: dense adhesions and hostile anatomy, uncontrolled bleeding, suspected gallbladder cancer requiring oncological resection, some cases of cholecystoenteric fistula and gallstone ileus, haemodynamic instability, and conversion from laparoscopy. Particularly when the hepatocystic triangle is unclear, conversion is not a complication but a sound safety decision. Predictors of conversion include severe acute or gangrenous cholecystitis, male sex, obesity, previous upper abdominal surgery, a thick-walled gallbladder and delayed presentation. Compared with laparoscopy, open surgery brings more pain, a longer stay and higher morbidity and mortality — largely reflecting a sicker population and more complex disease.

Gallbladder Polyps and Cancer Risk

Gallbladder polyps are found in up to about 7 percent of adults on ultrasound; the great majority, however, are not neoplastic (cholesterol polyps, adenomyomatosis). Only adenomas are precancerous, and gallbladder cancer is generally rare — but extremely lethal once advanced. A large meta-analysis covering 82 studies and 67,837 patients estimated the cumulative cancer risk of a polyp of 10 mm or less at about 0.6 percent. Management guidance has shifted in recent years towards a more nuanced and less interventional stratification:

• The 2022 European joint guideline (ESGAR, EAES, EFISDS, ESGE): cholecystectomy for a polyp of 10 mm or more in fit and consenting patients, or for a 6–9 mm polyp together with a malignancy risk factor (age over 60, primary sclerosing cholangitis, Indian or South Asian ethnicity, sessile morphology); ultrasound surveillance at 6 months and 1 and 2 years for the rest; surgery for growth to 10 mm or for 2 mm growth in the presence of a risk factor.
• The 2022 SRU consensus (imaging): it foregrounds morphology with very low, low and indeterminate risk categories; it raises the surgical threshold to about 15 mm for low-risk morphology and reduces the surveillance burden; polyps under 6 mm generally require no surveillance.

Real-world data (the POLYP study, 2025) show that the guidelines still lead to cholecystectomy for many benign polyps — underlining the need for better risk models. Porcelain gallbladder, chronic Salmonella carriage, large stones, primary sclerosing cholangitis and an abnormal pancreaticobiliary junction are further cancer contexts that may prompt consideration of cholecystectomy.

Postoperative Care, Complications and ERAS

Enhanced recovery (ERAS)

Elective laparoscopic cholecystectomy is increasingly performed as day-case or ambulatory surgery on ERAS principles: minimised fasting and preoperative carbohydrate loading, opioid-sparing multimodal analgesia (non-steroidal anti-inflammatories and paracetamol, local anaesthetic infiltration), nausea and vomiting prophylaxis, early mobilisation and oral intake, and avoidance of unnecessary drains. ERAS shortens stay and improves recovery without increasing complications (moderate to high certainty).

Complications

Bile duct injury is the most feared complication; it brings major long-term morbidity, the need for hepaticojejunostomy, and reductions in quality of life and life expectancy. Prevention rests on the Critical View of Safety, generous use of bail-out techniques, intraoperative cholangiography or fluorescence imaging when the anatomy is unclear, and a low threshold for calling for help or converting. The Strasberg classification (A–E) grades injuries from minor leaks to major duct transections. Early recognition and referral to a hepatobiliary centre markedly improve outcomes.

Bile leaks (cystic stump or accessory duct) typically present days after surgery with pain, fever or bilious drain output and are usually managed with ERCP plus sphincterotomy or stenting and percutaneous drainage of collections. Retained and recurrent duct stones are cleared endoscopically. Post-ERCP pancreatitis complicates biliary endoscopy in 5–7 percent of cases.

Post-cholecystectomy Syndrome and Physiological Adaptation

Physiological adaptation. After cholecystectomy, loss of the bile reservoir means that bile flows continuously into the duodenum rather than in concentrated boluses. The common bile duct often dilates slightly and takes on some reservoir function, the bile acid pool cycles more frequently and the enterohepatic dynamics are reset. Most people digest fat normally; in a subgroup, the handling of large fatty loads changes and the passage of bile acids into the colon increases.

Post-cholecystectomy syndrome describes persistent or new upper abdominal and biliary symptoms after surgery; it affects perhaps 5–40 percent of patients transiently and about 10–15 percent persistently. The causes fall into three groups:

• Biliary causes: retained or recurrent duct stones, a stone-bearing cystic stump or gallbladder remnant, bile leak or stricture, sphincter of Oddi dysfunction.
• Non-biliary causes (often the true cause of pre-existing symptoms mistaken for biliary ones): gastro-oesophageal reflux, peptic ulcer, functional dyspepsia and irritable bowel syndrome, pancreatitis and — frequently — bile acid (choleretic) diarrhoea.
• Alternative diagnoses missed before surgery.

Assessment is guided by the symptom pattern: liver tests and lipase, ultrasound, then MRCP or endoscopic ultrasound if a retained stone is suspected; manometry and ERCP only in carefully selected sphincter cases — bearing in mind that the EPISOD trial showed sphincterotomy to be of no benefit in suspected type III dysfunction. Bile acid diarrhoea responds well to sequestrants (cholestyramine, colesevelam). Management is aetiology-specific; for most patients reassurance and dietary adjustment suffice.

Long-Term Outcomes and Quality of Life

In symptomatic gallstone disease, cholecystectomy provides durable relief in the great majority; patient satisfaction is high and the gain in quality of life is marked. Most biliary symptoms resolve; dyspeptic symptoms of non-biliary origin may persist. A minority develop post-cholecystectomy syndrome or bile acid diarrhoea. Population data have examined links between cholecystectomy and subsequent metabolic and colorectal outcomes (altered bile acid flux and MAFLD; a small and contested association with right-sided colonic neoplasia); causality, however, is unresolved, and these signals do not warrant avoiding an indicated operation. Overall the benefit-risk balance strongly favours cholecystectomy in symptomatic and complicated disease.

Recurrence after duct clearance. After endoscopic clearance of the common bile duct, stones recur in 10–25 percent on follow-up, driven by persistently lithogenic bile, biliary stasis (periampullary diverticulum, a dilated or angulated duct), duodenobiliary reflux after sphincterotomy with bacterial colonisation (favouring brown pigment stones), and downward migration of stones remaining in the gallbladder. Cholecystectomy after duct clearance reduces recurrent biliary events and is recommended in most patients — during the same admission where possible. Adjunctive oral dissolution modestly lowers recurrence in some studies; correcting stasis is the key.

Special Patient Populations

Pregnancy. Stones and biliary sludge are common in pregnancy (oestrogen and progesterone effects). Uncomplicated biliary colic is managed conservatively where possible; recurrent or complicated symptomatic disease, however, must be treated — laparoscopic cholecystectomy is considered safe in every trimester (the second is optimal), and deferring a necessary operation increases maternal and fetal risk through recurrent attacks. In choledocholithiasis and cholangitis, ERCP with fetal shielding is used when required.

Paediatric patients. Historically pigment stones (haemolytic disease — sickle cell disease, spherocytosis, thalassaemia) predominated; paediatric cholelithiasis increasingly reflects obesity-related cholesterol stones. Laparoscopic cholecystectomy is indicated for symptomatic stones and is often combined with splenectomy in hereditary haemolytic disease. Ceftriaxone can cause reversible biliary pseudolithiasis.

Older patients. Older patients present later, with more complications and higher rates of gangrene, perforation and choledocholithiasis. Age alone is not a contraindication: early laparoscopic cholecystectomy is safe and recommended in the fit older patient and avoids the high mortality of recurrent emergencies. Frailty, comorbidity and severity grade determine the balance between early surgery, drainage and non-operative management within shared decision-making.

Future Technologies and Innovations

Fluorescence-guided surgery (near-infrared cholangiography with indocyanine green). Indocyanine green given intravenously is excreted in bile and fluoresces under near-infrared light, displaying extrahepatic biliary anatomy in real time without radiation or ductotomy. Randomised-trial-level evidence (8 studies, 1,586 patients) shows that the method markedly improves recognition of the common bile duct, with a short learning curve and easy integration. However, the trials are not powered to demonstrate a reduction in bile duct injury (odds ratio 0.73; wide confidence interval), and optimal dose and timing are not standardised (studies such as DOTIG favour low doses of 0.05–0.1 mg/kg given well before dissection). The method is becoming routine, particularly on robotic platforms.

Artificial intelligence in surgery and imaging. Artificial intelligence is advancing on several fronts: intraoperative computer vision that recognises the Critical View of Safety and go/no-go zones and warns against unsafe dissection; AI-assisted radiology that detects stones, polyps and duct stones and automatically stratifies duct-stone risk; AI-assisted endoscopy for lesion detection and ERCP guidance; and predictive analytics for conversion, complications and difficult-cholecystectomy scoring. These tools are promising but mostly at the validation and early-adoption stage; they need prospective outcome evidence and attention to bias and generalisability.

Personalised medicine and genetic risk prediction. Expanding genome-wide association studies and polygenic risk scores (around ABCG5/8, ABCB4, CYP7A1, TM4SF4 and new loci) may in future identify high-risk individuals for targeted prevention and screening. Digital twins are an emerging concept for surgical planning and individualised prediction, still largely in their infancy.

New bile acid and metabolic therapies. FXR agonists and FGF19 analogues developed for cholestatic and metabolic liver disease raise the possibility of pharmacological stone prevention by modulating the pathways that govern stone formation (CYP7A1, biliary cholesterol and bile acid secretion); stone-specific efficacy and safety data, however, are limited. Cholesterol absorption and secretion targets (for instance ezetimibe, which inhibits NPC1L1) are mechanistically interesting.

Microbiome-based prevention. A rapidly growing literature links the gut and biliary microbiome to stone formation: faecal microbiota from stone patients transferred stone susceptibility to mice through altered secondary bile acid production and increased cholesterol absorption; hydrogen sulfide derived from Desulfovibrionales activated hepatic FXR and suppressed CYP7A1, increasing biliary cholesterol secretion. This suggests future probiotic and prebiotic approaches, bile salt hydrolase modulation or diet-microbiome strategies — for now at the hypothesis-generating level (mechanistic, animal and Mendelian randomisation).

International Guidelines

Ongoing Clinical Trials

Statuses change; ClinicalTrials.gov and the World Health Organization ICTRP should be searched for the most current studies. The list above is illustrative, not exhaustive.

Discrepancies Between the Two Sources

This review is blended from two independent evidence syntheses. The sources diverged on the following points; rather than collapsing them into a single number, both are reported and reconciled. This is also a good map of why the gallstone literature remains numerically soft.

Evidence Comparison (GRADE Synthesis)

Certainty varies markedly from question to question. The strongest evidence supports the superiority of laparoscopy over open surgery and early surgery in acute cholecystitis; robotic equivalence is of moderate certainty; and microbiome, FXR and genetics-based prevention is still of very low certainty for clinical use.

Research Gaps

1. Silent stones: genetic and imaging biomarkers that identify in advance the minority who will develop complications.
2. The duct stone pathway: the optimal choice among preoperative ERCP, single-session laparoscopic surgery with duct exploration, and the rendezvous technique; and further reducing the rate of negative ERCP.
3. Robotic cholecystectomy: adequately powered randomised trials for bile duct injury and cost-effectiveness; clarification of the learning curve and the safety signal.
4. Fluorescence cholangiography: definitive, adequately powered randomised trials with standardised dose and timing for injury reduction.
5. Medical prevention: whether FXR/FGF19, ezetimibe or microbiome interventions can safely prevent stones in high-risk groups.
6. Polyp management: risk models that reduce cholecystectomy for benign polyps without missing cancer.
7. Post-cholecystectomy syndrome and bile acid diarrhoea: better prediction, prevention and management; the role of sphincter intervention after EPISOD.
8. Long-term metabolic and oncological outcomes: causality or confounding?

Clinical Recommendations

1. Do not operate on genuinely asymptomatic stones in most patients (moderate certainty); reserve prophylactic surgery for defined high-risk situations.
2. Recommend elective laparoscopic cholecystectomy in symptomatic cholelithiasis (high certainty) — symptoms recur and complications accumulate.
3. Perform early laparoscopic cholecystectomy in acute calculous cholecystitis in operable patients, preferably within seven days and during the same admission (high certainty).
4. Grade severity according to Tokyo 2018; reserve drainage for patients who are genuinely unfit, and prefer early surgery whenever feasible (CHOCOLATE).
5. Stratify the probability of duct stones according to ASGE 2019; use MRCP or endoscopic ultrasound at intermediate risk; reserve ERCP for high-probability or confirmed stones and for cholangitis.
6. Use UDCA dissolution only in carefully selected non-surgical patients (small, non-calcified cholesterol stones, functioning gallbladder); counsel them about its slowness and about recurrence.
7. Achieve the Critical View of Safety; use bail-out techniques and intraoperative imaging generously; convert to open surgery without hesitation (high certainty for the safety principle).
8. Robotic cholecystectomy is an acceptable alternative but not superior; adopt it on the basis of expertise and cost while heeding the safety signal.
9. Perform cholecystectomy during the same admission after gallstone pancreatitis or duct clearance (high certainty).
10. Treat post-cholecystectomy symptoms according to their cause; use bile acid sequestrants for choleretic diarrhoea and avoid unnecessary sphincter intervention.

Final Conclusions

Gallstone disease is a common disorder with metabolic and microbial roots whose clinical burden arises from the minority who progress to biliary pain and complications. The diagnostic pathway is well established — ultrasound first, then a stepwise approach to duct stones — and the treatment paradigm is mature: laparoscopic cholecystectomy is safe, definitive and the global standard; early surgery in acute cholecystitis and risk-stratified ERCP for duct stones are its central principles; and the anchor of all of it is a safety culture that prevents bile duct injury.

Robotic and single-incision approaches have widened the toolbox but have not dethroned laparoscopy on outcomes; oral dissolution occupies a small niche. The frontier is shifting away from removing the gallbladder more elegantly towards preventing the stone and making it impossible for surgery to injure the bile duct: near-infrared fluorescence and AI-assisted anatomy recognition to eliminate injury; genetic, bile acid and microbiome-based strategies to prevent the stone in the first place. Turning that promise into reality will require adequately powered studies with hard clinical endpoints that close the stubborn gap running through the whole field — the distance between mechanistic plausibility and demonstrated patient benefit.

Plain Language Patient Guide

What is a gallstone, and do I have to have surgery?

The gallbladder is a small sac that stores the bile produced by the liver. Stones that form inside it are very common — but what matters is not the presence of the stone, it is whether it causes symptoms. Most stones that cause no symptoms and are found incidentally stay silent for life; that is why surgery is usually unnecessary for symptom-free stones and observation is enough. For stones that cause pain, by contrast, surgery — removal of the gallbladder — is recommended, because the symptoms recur and the risk of complications rises over time.

What do the symptoms feel like?

The most typical symptom is a constant pain, often appearing after a fatty meal, in the upper right or upper middle abdomen, sometimes radiating to the right shoulder and back, lasting from half an hour to a few hours. Nausea often accompanies it.

Which operation is performed?

In almost all patients the keyhole (laparoscopic) method is used: the gallbladder is removed through a few small incisions using a camera and instruments. This method means little pain, quick recovery and often same-day discharge; it is the gold standard worldwide. If the anatomy cannot be seen clearly, your surgeon may leave part of the gallbladder in place (subtotal) or convert to open surgery, prioritising safety — this is not a failure but a correct and safe decision.

Is robotic surgery better?

For ordinary gallbladder surgery, no. Robotic surgery is safe and feasible, but good-quality studies have shown no clear additional benefit to the patient compared with the keyhole method; moreover it takes longer, costs more, and some data carry a signal that calls for caution regarding bile duct injury. In other words, asking for it to be done with the robot will not give you a better outcome in a standard gallbladder operation.

Recovery and life after surgery

Most patients are discharged as a day case or after one night and return to a normal diet within weeks. Because bile now flows continuously into the bowel without being stored, some people experience temporary fat intolerance, bloating or diarrhoea; this usually settles on its own, and if it persists, bile acid binding medicines are effective. A permanently strict diet is unnecessary for most patients. A small group experience symptoms that persist after surgery (post-cholecystectomy syndrome); most of these are in fact caused by other conditions such as reflux, stomach problems or bile diarrhoea and are treated according to the cause.

The risks you should know about

Modern cholecystectomy is very safe. Nevertheless, like any operation it has risks: the most serious but rare one is bile duct injury (roughly 1 in every 200–500 operations); there may also be bile leak, bleeding, infection and stones left in the bile duct. Most of these risks are low in experienced hands and with the right techniques. For a stone that causes symptoms, the benefit of surgery clearly outweighs these risks.

Glossary and Abbreviations

References

1. Buch, S., Schafmayer, C., Völzke, H., et al. (2007). A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nature Genetics, 39(8), 995–999. https://doi.org/10.1038/ng2101
2. Buxbaum, J. L., Abbas Fehmi, S. M., Sultan, S., et al. (2019). ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointestinal Endoscopy, 89(6), 1075–1105. https://doi.org/10.1016/j.gie.2018.10.001
3. Costa, C. J., Nguyen, M. T. T., Vaziri, H., & Wu, G. Y. (2024). Genetics of gallstone disease and their clinical significance: A narrative review. Journal of Clinical and Translational Hepatology, 12(3), 316–326. https://doi.org/10.14218/JCTH.2023.00563
4. Cotton, P. B., Durkalski, V., Romagnuolo, J., et al. (2014). Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction (EPISOD). JAMA, 311(20), 2101–2109. https://doi.org/10.1001/jama.2014.5220
5. Ferkingstad, E., Oddsson, A., Gretarsdottir, S., et al. (2018). Genome-wide association meta-analysis yields 20 loci associated with gallstone disease. Nature Communications, 9, 5101. https://doi.org/10.1038/s41467-018-07460-y
6. Foley, K. G., Lahaye, M. J., Thoeni, R. F., et al. (2022). Management and follow-up of gallbladder polyps: Updated joint guidelines (ESGAR, EAES, EFISDS, ESGE). European Radiology, 32(5), 3358–3368. https://doi.org/10.1007/s00330-021-08503-7
7. Global epidemiology of gallstones in the 21st century: A systematic review and meta-analysis. (2024). Clinical Gastroenterology and Hepatology, 22(8), 1586–1595. https://doi.org/10.1016/j.cgh.2024.01.051
8. Estimating global prevalence of gallbladder stones from 2000 to 2024: A systematic review and meta-analysis. (2025). Annals of Medicine, 57(1). https://doi.org/10.1080/07853890.2025.2570795
9. Gurusamy, K. S., & Davidson, B. R. (2014). Gallstones. BMJ, 348, g2669. https://doi.org/10.1136/bmj.g2669
10. Hu, H., Shao, W., Liu, Q., et al. (2022). Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion. Nature Communications, 13, 252. https://doi.org/10.1038/s41467-021-27758-8
11. Kalata, S., Thumma, J. R., Norton, E. C., Dimick, J. B., & Sheetz, K. H. (2023). Comparative safety of robotic-assisted vs laparoscopic cholecystectomy. JAMA Surgery, 158(12), 1303–1310. https://doi.org/10.1001/jamasurg.2023.4389
12. Kamaya, A., Fung, C., Szpakowski, J. L., et al. (2022). Management of incidentally detected gallbladder polyps: SRU consensus conference recommendations. Radiology, 305(2), 277–289. https://doi.org/10.1148/radiol.213079
13. Loozen, C. S., van Santvoort, H. C., van Duijvendijk, P., et al. (2018). Laparoscopic cholecystectomy versus percutaneous catheter drainage for acute cholecystitis in high-risk patients (CHOCOLATE). BMJ, 363, k3965. https://doi.org/10.1136/bmj.k3965
14. López-Sánchez, J., Garrosa-Muñoz, S., Pardo-Aranda, F., et al. (2024). Dose and administration time of ICG in near-infrared fluorescence cholangiography (DOTIG): A randomized clinical trial. Surgical Endoscopy. PMID 39820601
15. May, G. R., Sutherland, L. R., & Shaffer, E. A. (1993). Efficacy of bile acid therapy for gallstone dissolution: A meta-analysis of randomized trials. Alimentary Pharmacology & Therapeutics, 7(2), 139–148.
16. Peery, A. F., Crockett, S. D., Murphy, C. C., et al. (2019). Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology, 156(1), 254–272. https://doi.org/10.1053/j.gastro.2018.08.063
17. Pisano, M., Allievi, N., Gurusamy, K., et al. (2020). 2020 WSES updated guidelines for the diagnosis and treatment of acute calculous cholecystitis. World Journal of Emergency Surgery, 15(1), 61. https://doi.org/10.1186/s13017-020-00336-x
18. Comparison between open, laparoscopic, and robotic cholecystectomy: A systematic review and meta-analysis. (2026). The American Journal of Surgery.
19. Indocyanine green fluorescent cholangiography in laparoscopic cholecystectomy: A systematic review and meta-analysis with trial sequential analysis. (2025). Surgery. PMID 39891966
20. Siby, J., Singh, K. K., & Sajid, M. S. (2024). Laparoscopic versus robotic cholecystectomy: A systematic review with meta-analysis. Translational Gastroenterology and Hepatology, 9, 3. https://doi.org/10.21037/tgh-23-56
21. Sheetz, K. H., & Dimick, J. B. (2024). Learning curve for robotic-assisted cholecystectomy: Surgeon-level volume and bile duct injury risk. JAMA Surgery, 159(6), e241243. https://doi.org/10.1001/jamasurg.2024.2243
22. Strasberg, S. M., & Brunt, L. M. (2010). Rationale and use of the critical view of safety in laparoscopic cholecystectomy. Journal of the American College of Surgeons, 211(1), 132–138. https://doi.org/10.1016/j.jamcollsurg.2010.02.053
23. Brunt, L. M., Deziel, D. J., Telem, D. A., et al. (2020). Safe cholecystectomy multi-society practice guideline. Annals of Surgery, 272(1), 3–23. https://doi.org/10.1097/SLA.0000000000003791
24. van den Bos, J., Schols, R. M., Luyer, M. D., et al. (2016). NIRF cholangiography-assisted laparoscopic cholecystectomy (FALCON trial): Study protocol. BMJ Open, 6(8), e011668. https://doi.org/10.1136/bmjopen-2016-011668
25. Woldehana, N. A., Jung, A., Parker, B. C., et al. (2025). Clinical outcomes of laparoscopic vs robotic-assisted cholecystectomy in acute care surgery. JAMA Surgery, 160(7), 755–762. https://doi.org/10.1001/jamasurg.2025.1291
26. Yokoe, M., Hata, J., Takada, T., et al. (2018). Tokyo Guidelines 2018: Diagnostic criteria and severity grading of acute cholecystitis. Journal of Hepato-Biliary-Pancreatic Sciences, 25(1), 41–54. https://doi.org/10.1002/jhbp.515